International trends in clozapine use: a study in 17 countries

Bachmann, C. J., Aagaard, L., Bernardo, M., Brandt, L., Cartabia, M., Clavenna, A., Coma Fusté, A., Furu, K., Garuoliené, K., Hoffmann, F., Hollingworth, S., Huybrechts, K. F., Kalverdijk, L. J., Kawakami, K., Kieler, H., Kinoshita, T., López, S. C., Machado‐Alba, J. E., Machado‐Duque, M. E., Mahesri, M., Nishtala, P. S., Piovani, D., Reutfors, J., Saastamoinen, L. K., Sato, I., Schuiling‐Veninga, C. C. M., Shyu, Y.‐C., Siskind, D., Skurtveit, S., Verdoux, H., Wang, L.‐J., Zara Yahni, C., Zoëga, H., Taylor, D.·2017·Acta Psychiatrica Scandinavica
DOI 10.1111/acps.12742

Cited by (312)

Items 301–312 of 312

  1. Clozapine Beyond Walls: Community Clozapine Initiation in Early Psychosis
    Rajeev Krishnadas, Emilio Fernández-Egea · 2026 · Schizophrenia Bulletin
  2. Seizures associated with clozapine augmentation by other antipsychotics: a pharmacovigilance–pharmacodynamic analysis using VigiBase
    Masakazu Hatano, Hirofumi Hamano, Masaya Kanda, Takenao Koseki, Tsuyoshi Nakai, Rina Horii, Nozomi Yoshihara, Takeo Saito, Kenshi Takechi, Satoru Esumi et al. · 2026 · Therapeutic Advances in Psychopharmacology
  3. Guideline adherence in patients with long-term schizophrenia in Germany: Focus on clozapine and electroconvulsive therapy
    Berend Malchow, Paul-Fabian Mühl, Michael Belz, Anke Bramesfeld, Elias M. Wagner, Jens Wiltfang, Alkomiet Hasan, David Zilles‐Wegner · 2026 · Pharmacopsychiatry
  4. Clinical response to clozapine in Black people with psychosis: A secondary analysis of an open-label clinical trial
    Allison S. Brandt, Gopal R. Vyas, Taiwo Olamide Oduguwa, Adeola Adebayo, Heather A. Adams, Raymond C. Love, Russell L. Margolis, Robert W. Buchanan, Richard A. Adebayo, Deanna L. Kelly · 2026 · Therapeutic Advances in Psychopharmacology
  5. Myocarditis monitoring during clozapine initiation: audit of practice in an NHS trust
    Madelaine Bridges, Agostina Secchi, Yash Kumar, Von-de viel Nettey, Jagdip Bahia, Eromona Whiskey, Sukhwinder Singh Shergill · 2026 · BJPsych Open
  6. Patients Receiving 100 or More Electroconvulsive Therapy Treatments in a Nationwide Cohort
    Masahiro Hata, Yuki Miyazaki, Shun Takahashi · 2026 · Acta Psychiatrica Scandinavica
  7. Predicting clozapine initiation among patients with schizophrenia via machine learning trained on electronic health record data
    Erik Perfalk, Jakob Grøhn Damgaard, Andreas Aalkjær Danielsen, Søren Dinesen Østergaard · 2026 · Schizophrenia Research
  8. Prevalence of Treatment‐Resistant Schizophrenia: A Nationwide Multicenter Study
    Yusuke Arai, Toru Horinouchi, Hiroyuki Muraoka, Junya Matsumoto, Kazuhiko Yamamuro, Toshinori Nakamura, Hisashi Yamada, Toshiaki Onitsuka, Yuka Yasuda, Naoki Hashimoto et al. · 2026 · Neuropsychopharmacology Reports
  9. International trends in clozapine utilisation prevalence in adults, adolescents and older people: An observational study in 42 countries between 2015–2024
    Oliver H. F. Scholle, Heidi T. Taipale, Michael Dörks, Jannik Ohmes, Lise Aagaard, Oleg Aizberg, Salim Al‐Huseini, Mohamed Abdalhameed Alnor, Stojan Bajraktarov, Paolo Bertolini et al. · 2026 · medRxiv
  10. Clozapine and Solid Cancer Risk in Lithuania: A Population-Based Cohort Study
    Mingailė Drevinskaitė, Arūnas Germanavičius, Giedrė Smailytė · 2026 · Journal of Clinical Medicine
  11. Impact of 2025 REMS discontinuation on clozapine prescribing: An Interrupted Time Series analysis
    Julia Preusch, Wesley Hill, Jeremiah Hopkins, Wanhong Zheng · 2026 · Schizophrenia Research
  12. Antipsychotic Prescriptions for Prenatal and Postpartum Women in Japan: A Large Claims Database Study
    Ryo Daniel Obara, Takamasa Sakai, Tomofumi Ishikawa, Kei Morishita, Motohiko Adomi, Azusa Hara, Saya Kikuchi, Natsuko Kobayashi, Noriyuki Iwama, Genki Shinoda et al. · 2026 · Pharmacology Research & Perspectives